Racura Oncology Ltd (ASX:RAC)
Australia · Delayed Price · Currency is AUD 2.130
-0.090 (-4.05%)
Jul 17, 2026, 4:10 PM AEST
Racura Oncology Earnings Call Transcripts
Fiscal Year 2025
-
Discovery of EE bisantrene as the sole active isomer led to three new patents, securing up to 25 years of exclusivity and significant commercial potential. RC110 is phase three ready, and partnering efforts focus on Asia-Pacific, with robust protocols ensuring only EE is administered.
Fiscal Year 2024
-
The AGM highlighted major progress in advancing RC220 bisantrene to clinical trials, board renewal, and strategic focus on cardioprotection and anti-cancer indications. Shareholder resolutions were addressed, and the company emphasized prudent resource management and scientific innovation.